Safety evaluation and toxicology studies and related services for drug development
Active Awarded
- Contract number
- 75N95024D00019
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- Safety Evaluation and Toxicology Studies and Related Services for Drug Development Pre-Solicitation · 75N95023R00029 · Posted May 11, 2023
- Last date to order 39% complete
- IDV ceiling
- $48,622,546.00
- Maximum order
- $48,622,546.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The federal contract IDV award is for safety evaluation and toxicology studies and related services to support drug development efforts of the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The prime contractor, SRI International, a nonprofit research and development institute, will provide in vitro and in vivo exploratory and Investigational New Drug (IND)-directed toxicology studies for small molecule and biologic therapeutic candidates. This $48.6 million multiple-award IDIQ contract has a 6-year ordering period from June 2024 to June 2030. The contract aims to support safety assessments for therapeutic targets, lead optimization, and compound selection processes, as well as generating data for regulatory submissions such as IND applications and New Drug/Biologics License Applications. Contractors must have the appropriate certifications to conduct toxicology studies under relevant guidelines and regulations.
The original pre-solicitation notice indicates that the acquisition will be competed on a full and open basis without set-asides. The work will primarily be performed at the contractor's facilities. This contract supports NCATS' mission to advance translational research and move therapeutic candidates through preclinical development to IND filing and potentially early clinical trials.
Quick answers
Who was awarded contract 75N95024D00019?
75N95024D00019 was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on June 20, 2024.
How much is contract 75N95024D00019 worth?
75N95024D00019's own ceiling is $48,622,546. A single order can be worth up to $48,622,546.
Which agency awarded contract 75N95024D00019?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95024D00019, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Who can order from contract 75N95024D00019?
75N95024D00019 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N95024D00019 part of a contract vehicle?
Yes. 75N95024D00019 is part of Safety Evaluation and Toxicology Studies and Related Services for Drug Development.
Was contract 75N95024D00019 competed?
The extent of competition for 75N95024D00019 was full and open competition. The government received 6 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV